Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

By sjmartinez • January 13, 2025

Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025 Jan 8:S0140-6736(24)02575-3. doi: 10.1016/S0140-6736(24)02575-3. Epub ahead of print. PMID: 39798578.

Tags: Hematology/Oncology, Publications

Related Posts

Feasibility of cognitive testing and ecological momentary assessments using smartphones in middle aged and older adults with insomnia

Ghadimi S, Ereso J, Kaula AJ, Taptiklis N, Cormack F, Alessi C, Martin JL, Dzierzewski JM, Naeim A, Kremen S, Te T, Fung CH. Feasibility[...]

A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Gorman S, Compton N, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson[...]

A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma

Amaral LJ, Gresham G, Kim S, Tighiouart M, Nelson TA, Welborn A, Lockshon L, Noorvash B, Rudnick JD, Irwin SA, Freedland SJ, Hu J. A[...]